Clinigen logo

CLIN - Clinigen News Story

848.5p 11.5  1.4%

Last Trade - 07/05/21

Mid Cap
Market Cap £1.13bn
Enterprise Value £1.48bn
Revenue £518.7m
Position in Universe 410th / 1821

Clinigen Group plc - Directorate Change

Wed 24th March, 2021 9:00am
RNS Number : 3169T
Clinigen Group plc
24 March 2021

24th March 2021




Clinigen appoints Sharon Curran as independent Non-Executive Director


Clinigen Group plc (AIM: CLIN, 'Clinigen'), the global pharmaceutical Products and Services company, has appointed Sharon Curran as a new independent Non-Executive Director, effective from 27 April 2021.


Sharon is an experienced non-executive board director as well as having proven top-level experience in leading high impact global marketing, commercialisation and growth strategies for world class pharmaceutical corporations (AbbVie, Abbott Pharmaceuticals and Eli Lilly).


She is currently a Non-Executive Director for Circassia Group plc where she is Chair of the Remuneration Committee. She is also on the Board of Morphosys AG (Audit & Risk Committee). Before taking these roles, she was VP, Global Marketing and Commercial Operations at AbbVie where she worked from 2012 to 2017. Whilst there, she was on the ethics & compliance committee, involved in portfolio strategy and was part of the global crisis management team. Previously, she was Global Brand and Regional Commercial Director at Abbott Pharmaceuticals (2009-2012) and before then, she was Divisional Head, Strategy & Operations (Ireland & UK Affiliate) for Eli Lilly (1999-2008). She has a MSc in Business Administration from Trinity College, Dublin and a B.Sc in Biotechnology from Dublin City University. She has a Chartered Director Program Diploma from the Institute of Directors.


Peter Allen, Chairman of Clinigen, said:


"One area of focus for Clinigen over the past 12 months has been to bring new expertise onto the Board from industry and from other company boards. We are fortunate with Sharon that she has an equal measure of both. She has worked for multinational companies in the US and Europe, both in active executive positions as well as senior advisory on ethics and compliance, portfolio strategy and global crisis management. She has gone on to develop a broad portfolio of non-executive director roles with a variety of European companies. She is a welcome addition to the Clinigen Board and we look forward to her joining in April."



The following information is disclosed pursuant to AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies


Sharon Evelyn Curran, aged 52 years, is currently a director of the following companies:


Current directorships

§ Circassia Group plc

§ Morphosys AG

§ CAT Capital BidCo Ltd

§ CAT Capital TopCo Ltd



There is no further information to be disclosed pursuant to AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.


- Ends -



Contact details

Clinigen Group plc

Tel: +44 (0) 1283 495010

Shaun Chilton, Chief Executive Officer

Nick Keher, Chief Financial Officer




Numis Securities Limited - Nominated Adviser & Joint Broker

Tel: +44 (0) 20 7260 1000

James Black / Garry Levin / Freddie Barnfield



RBC Capital Markets - Joint Broker

Tel: +44 (0) 20 7653 4000

Marcus Jackson / Elliot Thomas




Instinctif Partners

Tel: +44 (0) 20 7457 2020

Melanie Toyne-Sewell / Tim Linacre / Rozi Morris / Phillip Marriage



Notes to Editors


About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global, specialist pharmaceutical services and products platform focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time. The Group operates from sites in North America, Europe, Africa and the Asia Pacific.

Clinigen has more than 1,250 employees across five continents in 16 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 34 of the top 50 pharmaceutical companies; interacting with over 5,000 hospitals across more than 115 countries.

For more information on Clinigen, please visit 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.